Rationale and design of a randomised phase II multicentre crossover trial investigating a sodium-glucose co-transporter 2 inhibitor, dapagliflozin, combined with a novel continuous ketone monitor in adults with type 1 diabetes to reduce the risk of diabetic ketoacidosis: the PARTNER study.

Ngan J, Kong YW, Goad J, Huang MLH, Jenkins A, Vogrin S, Trawley S, Manzoney A, Nakano M, Ekinci E, Kriketos A, Fourlanos S, Boisseau L, Nolan CJ, Taylor P, Fenn J, Stranks SN, O'Neal DN

Open source

DOI: 10.1136/bmjopen-2024-098457
Published: 2025 May 6
Container: BMJ open
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/bmjopen-2024-098457,
  title = {Rationale and design of a randomised phase II multicentre crossover trial investigating a sodium-glucose co-transporter 2 inhibitor, dapagliflozin, combined with a novel continuous ketone monitor in adults with type 1 diabetes to reduce the risk of diabetic ketoacidosis: the PARTNER study.},
  author = {Ngan J and Kong YW and Goad J and Huang MLH and Jenkins A and Vogrin S and Trawley S and Manzoney A and Nakano M and Ekinci E and Kriketos A and Fourlanos S and Boisseau L and Nolan CJ and Taylor P and Fenn J and Stranks SN and O'Neal DN},
  year = {2025},
  journal = {BMJ open},
  doi = {10.1136/bmjopen-2024-098457},
  url = {https://doi.org/10.1136/bmjopen-2024-098457}
}

RIS

TY  - JOUR
TI  - Rationale and design of a randomised phase II multicentre crossover trial investigating a sodium-glucose co-transporter 2 inhibitor, dapagliflozin, combined with a novel continuous ketone monitor in adults with type 1 diabetes to reduce the risk of diabetic ketoacidosis: the PARTNER study.
AU  - Ngan J
AU  - Kong YW
AU  - Goad J
AU  - Huang MLH
AU  - Jenkins A
AU  - Vogrin S
AU  - Trawley S
AU  - Manzoney A
AU  - Nakano M
AU  - Ekinci E
AU  - Kriketos A
AU  - Fourlanos S
AU  - Boisseau L
AU  - Nolan CJ
AU  - Taylor P
AU  - Fenn J
AU  - Stranks SN
AU  - O'Neal DN
PY  - 2025
JO  - BMJ open
DO  - 10.1136/bmjopen-2024-098457
UR  - https://doi.org/10.1136/bmjopen-2024-098457
ER  -

APA

J, N., YW, K., J, G., MLH, H., A, J., S, V., S, T., A, M., M, N., E, E., A, K., S, F., L, B., CJ, N., P, T., J, F., SN, S., & DN, O. (2025). Rationale and design of a randomised phase II multicentre crossover trial investigating a sodium-glucose co-transporter 2 inhibitor, dapagliflozin, combined with a novel continuous ketone monitor in adults with type 1 diabetes to reduce the risk of diabetic ketoacidosis: the PARTNER study.. BMJ open. https://doi.org/10.1136/bmjopen-2024-098457

Source records

pubmed · retrieved 2026-09-26T07:42:32.919Z